IE
WINT

Israel Englander’s Windtree Therapeutics WINT Stock Holding History

Israel Englander’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed -$1K – 7554
2021
Q4 		$1K Hold
10
– – ﹤0.01% 6691
2021
Q3 		$2K Hold
10
– – ﹤0.01% 6709
2021
Q2 		$3K Hold
10
– – ﹤0.01% 6451
2021
Q1 		$3K Hold
10
– – ﹤0.01% 5831
2020
Q4 		$2.31M Buy
+10
New +$2.77M ﹤0.01% 3126

Other funds holding WINT

TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Israel Englander's WINT Position: Q1 2023 in Review

Israel Englander sold out of Windtree Therapeutics (WINT) in Q1 2023, closing a stake of 2 shares — an estimated $14K sold.

Israel Englander first reported a position in WINT in Q3 2020 and held it in 6 quarters. The position peaked at $552K in Q4 2020. 2 funds tracked by Wall St. Rank hold WINT as of Q1 2023.

  • Israel Englander reported no remaining Windtree Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Israel Englander sold 2 Windtree Therapeutics shares in Q1 2023, an estimated $14K.
  • Israel Englander first reported a position in Windtree Therapeutics in Q3 2020 and held it in 6 quarters.
  • Israel Englander's Windtree Therapeutics position peaked at $552K in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.